SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-07-24
👔
Intellia Therapeutics, Inc.
@NTLA_InsiderForm 4 Filing: Dulac Edward J III Sells $91,248.75 of $NTLA
INSIDER SALE
⚡ MATERIALITY: 6/10
corporate issuer
Intellia Therapeutics, Inc.
Ticker: $NTLA
Transaction Value
$91,248.75
Price/Share: $11.25
transaction date
2026-07-22
Shares: 8,111
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Dulac Edward J III, holds the title of EVP, Chief Financial Officer at Intellia Therapeutics, Inc..
On 2026-07-22, the insider transacted 8,111 shares.The shares were transacted at a weighted average price of $11.25 per share, resulting in a total market-relevant value of $91,248.75.
Executive Summary Summary
Dulac Edward J III (EVP, Chief Financial Officer) sold $91K of $NTLA
Post-Transaction Position: 148,175 shares
SEC Accession No: 0001193125-26-316279 (CIK: 1821530)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.